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INTRODUCTION
Considerable progress has been made recently in the study of cell differentiation mediated
by the thymus gland, particularly through studies conducted on mice (Millerl), Hirokawa2».
The objective of this study has been to extend our understanding in this field by identifying
some characteristics of functional disorders in the human thymus, namely:
A) inhibition of the maturation process in T-cells, and/or the possibility of a disorder of
'barrier mechanism' working against B-cell infiltration into the thymus of myasthenia gravis;
and, B) sensitivity to A TS for myasthenic thymocytes compared with the conditions of normal,
healthy thymus cells. The scope of this report has been limited to the pathological characteristics
of hyman thymus, studied through patients with one type of thymus disorder, i.e. those suffering
myasthenia gravis.
Although there are several studies 2 ),4) related to the cell constitution of normal thymus, there
are no previous studies investigating disorders of thymus of myasthenia gravis. Here the sub-
population of T and B-cells of myasthenia gravis and normal thymus are examined concurrently
and on a comparative basis.
MATERIALS AND METHODS
1) Preparation of thymocytes
Thymocytes were obtained from 10 myasthenic patients who had not been treated with corti-
costeroid therapy, but who had received thymectomy for treatment. Control thymocytes were
obtained from congenital heart disease patients during open heart surgery. These thymus cells
were cut, ground on a stainless steel mesh, and then suspended. Nucleated cells were purified
in the suspension by the Ficoll-Hypaque method. 5 ) The cell number of samples was set for these
tests at 5 X 10 6 jml.
2) Preparation of anti-thymocyte serum CATS)
Normal, healthy thymus cells were obtained as described above. Volumes of 1 mM EDTA
were added and mixed for 2 mins. at 37°C. To this solution a large volume of phosphate buffer
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saline was added to stop any more reaction. This fluid was centrifugified, and the supernatant
was then used as the membrane antigen of thymocytes. The quantity of this antigen was estimated
by Coleman's spectrometer (Hitachi, Tokyo, Japan). One mg of this antigen, emulsified in
Freund's complete adjuvant was injected tino a rabbit intracutaneously, two times, at one week's
interval. One week following the last injection, 0.5 mg of an alum precipitated form of this
antigen, was then injected intravenously into the same animal. One week later the blood was
harvested as the antithymocyte serum. This serum was inactivated at 56°C for 30 mins. and
absorbed thoroughly with human red blood cells (AB group), as well as the cultured cells of B-cell
human leukemia patients. This serum was then used for the cytotoxity test with guinea pig
serum as the complement.
a) T lymphocytes
i) E-rosette formation method.
0.2 ml of thymus cell samples were mixed in equal volume with sheep red blood cells
(SRBC at 1 X 10B/ml concentration) and centrifugified at 1000 rpm for 10 mins at room
temperature. After being brought to 4°C and left for an hour, this mixture was re-suspended
and the E-rosette forming cells were counted microscopically. Lynphocytes that combined
with more than four SRBC were counted as T-E (+) cells.
ii) Cytotoxicity test with anti-thymocyte serum.
Anti-thymocyte serum (ATS), obtained as described previously, was diluted to two dif-
ferent consistencies, i.e. 1 :16 and 1 :64. Then 50 fLI of each dilutant, including 40 fLl of ATS
and 10/1-1 of complement, were mixed together with the cell samples. The mixture was left
for 45 mins at 37°C. By this procedure the living cell count could be made microscopically
using the dye exclusion method. 6),7)
b) B lymphocytes: EAC-rosette formation method. 5 )
19S antibody was separated from the anti-SRBC serum prepared previously using Sepha-
dex G-200 and then diluted. This was then mixed with an equal volume of SRBC in sus-
pension (2 X 109/ml) and left for 30 mins at 37°C. This stage was followed by washing in
Galetin-Veronal buffer (GVB) and re-adjusted again to 2 X 109/ml of SRBC. A tenth volume
of fresh C57 BL/10 mouse serum was added and then left for 15 mins at 37°C. After
washing with GVB, it was again -readjusted to a concentration of 5 X 10s/ml of SRBC. 0.2
ml of this mixture (EAC) was added to an equal volume of thymocyte cells in suspension, and
left for an hour at 37°C. After being brought to 4°C and left for an hour, the EAC cells were
counted microscopically. Lymphocytes that combined with more than four EACs were
counted as B-EAC (+) cells.
RESULTS
1) Specificity of ATS
Cytotoxicity of ATS was shown to be effective on control thymocytes even if diluted 500 or
1000 fold (shown in Fig. 1). 50-600/0 normal peripheral lymphocytes were killed by this serum.
Cultured T-leukemia cells were also killed (100°,10) by this serum. However B-Ieukimia cells
were found to be resistant to this serum.
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Fig. 1 ATS showed sufficient cytotoxic effects upon normal thymocytes (X - X),
and T cell leukemia (0-0). On the other hand it didn't show any
cytotoxic effect upon B cell leukemia (6-6).
Table. 1 T and B Cell subpopulations for Normal Thymus
T-Cells B-Cells
Case No. Disease
T-ATS (%) T-E (%) B-AEC (%)
- --_.. ---_._--
1. S year-old male ASD 96 84 0
2. 8 year-old male ASD n.d.* 77 1.3
3. 32 year-old male ASD 99 70 2.6
4. 40 year-old male MS 98 71 0
5. 8 year-old female VSD 96 70 3
* not done
2) T and B-cell subpopulation in normal thymus
The percentages of T and B-cells found in normal, healthy thymus are shown in Table 1.
In four cases (Nos. 1, 3, 4 and 5) thymocytes were killed, thus nidicating that 96-99% of normal
hyman thymus consist of ATS sensitive cells (T-ATS). However, with the E-rosette formation
method (T-E), only 70-84% were detected in all cases. The number of B-cells detected as EAC
rosettes was 0~3%.
3) T and B-cell subpopulations in myasthenic thymus
Ten cases of T and B-cell subpopulations were investigated from myasthemia gravis patients
(Table 2). In 3 of these cases (Nos. 1, 2 and 10), due to the small thymoma in their thymuses,
cells were obtained and counted from both their thymomatous as well as non-thymomatous areas
of the thymus. In 2 cases (Nos. 5 and 6), since almost the whole of their thymuses were occupied
by large thymona, cell samples were obtained only from those thymomatous areas.
It can be seen from Table 2 that the proportion of B-cells (B-EAC) was significantly higher
at 10-30% for all myasthenic thymus, as compared with that of normal thymus. Conversely,
the T-cell proportion was somewhat lower than that of normal thymus cells.
In normal (control) thymus, the T-ATS value was high (more than 96%), as shown in Table 1.
The T -E value was also high, although usually about 20-30% lower than that of T -ATS. On
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Table. 2 T and B Cell subpopulations in myasthenia thymus
Clinical Classi- Complication of T-Cell B-CellCase No. fication of M.G --_.-_._-~---~- -----..
(Ossaman's) thymoma T-ATS (%) T-E (%) B-EAC (%)
--------------- ._-- ---
- ---- ----------- -
-----._---
---_ ...._-
1. 20 year-old male III (+) *[1) 86 76 n.d.2) 88 75 15
2. 22 year-old male IIA (+) *[1) 70 n.d. n.d.2) 83 n.d. n.d.
3. 24 year-old female IIB (- ) 92 69 1.3
4. 53 year-old male IIB (-) 72 n.d. n.d.
5. 28 year-old female IIB (+ ) ** 78 76 10
6. 65 year-old male lIB (+ ) ** n.d. 40 35
7. 28 year-old female lIB (-) n.d. 65 30
8. 20 year-old female IIB (-) n.d. 75 12
9. 31 year-old female IIB (-) 81 38 13
10. 53 year-old male IIA (+) {I) 69 42 22
2) 43 65 12
* Thymus complicated with thymoma was evaluated about their thymocytes obtained from thymo·
matous area 1), and from non-thymomatous area 2).
** Cells were obtained only from thymomatous area because thymoma was large enough to occupy
almost part of thymus.
n.d.: not done.
the other hand, it seems that a dissociation exists between the T-ATS and T-E values of myasthe-
nic thymus. No.9, for example, shows a T-E value of 43% while there were 81% T-cells detected
by ATS. For No. 10, on the other hand, the T-ATS value was smaller than that of the T-E
value. Cells, however, from thymomatous and non-thymomatous thymus did not differ.
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Fig. 2 In most cases, as shown by 1. The T-
A TS value in normal thymus was still
high until the A TS was diluted to low
concentration. But in only one case,
as shown by 2, the A TS value rapidly
decreased even when the A TS was dilu-
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Fig. 3 The T-ATS percentage ofmyasthemia showed
a comperatively lower cell count at high con-
centration of A TS. The cells in all cases
increase their resistance at low coneetration.
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Fig. 2 shows the percentages of T-ATS for normal (control) thymus cells when ATS was
diluted. As shown by graph path No.1 the T -ATS proportion remained more or less constant
until diluted 1 :512. In one, exceptional case, the cells were resistant to the killing by low concet-
rations of ATS, as indicated by graph path No.2, Fig. 2. On the other hand, as shown in Fig. 3
T-ATS percentage of myasthenic cells, in 3 out of 4 cases, showed a comparatively lower cell
count at high concentrations of ATS. The cells in all cases increase their resistance to ATS at
low concentrations.
DISCUSSION
It has been demonstrated, by others, that the pathological incidence of thymoma is high in
myasthenia. Up to the present time immunological studies of myasthenic thymus have not
achieved much. This investigation has been conducted so as to make a comparative analysis of
the T and 13-cell subpopulations in both normal and myasthenic thymuses with the purpose of
identifying some aspects that are characteristic of thymus disorders.
These results indicate the following:
1) In normal thymus, the proportion of T-cells are very high, while the B-cell populatin is
almost negligeable. The mean proportion of T-cells shown to be T-ATS was 97%' while those
found to be T-E were 74%, Thus T-ATS was 12-24% higher than that of T-E, including all
normal cases.
On the other hand, the proportion of 13-cells (13-EAC) in the myasthenic thymus was signi-
ficantly higher in contrast with normal (control) thymuses. Also a large number of Ig bearing
cells were detected in the analysis of the myasthenic cells by the immunofluorescence method
(unpublished data). Parkman,3) whose work on the analysis of human embryo thymocytes
showed that the thymocytes of the embryo up to the eight week demonstrated EAC-rosette (+)
and E-rosette (-) thymocytes. According to their results, the existance of the large number of
B-cells in myasthenic thymus may be due to some disorders in the maturation of thymus. It
seems possible that there may be some 'barrier mechanism' which prevents the invasion of 13-
lymphocytes into the thymus tissue in normal, healthy thymus cells, while for myasthenic thymus
some other disorder in the mechanism may promote, or rather, reduce the inhibitory process that
controls the B-Iymphocytes' entering the thymus tissue.
2) A further aspect resulting from this investigation was the apparent and significant dis-
sociation of the T-ATS and T-E percentages in the myasthnia samples. In normal thymus the
cells were sinsitive to low concentrations of ATS (Tables 1 and 2). Whereas in myasthenic cases
cells were resistant to the low concentration of ATS. However, one case of myasthenia showed
almost as high a T-ATS proportion as normal thymus at high concentrations, although cells of
this case ware resistant when diluted by only 4 or 8 times. It may be that for myasthenia gravis,
the surface determinants of the thymocyte antigen may be different from the surface receptor fo
SRBC, and that the thymocyte antigen may also be different from that of normal thymocytes in
their quantity and/or quality.
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SUMMARY
Bull. Chest Dis. Res. Inst., Kyoto Univ.
A clinico-pathological investigation was performed, examining T and B-cell subpopulations
of normal and myasthenia thymus.
The proportion of T -cells in healthy human thymus was found to be high (96-99% ), as detect-
ed by the cytotoxicity method using the antithymocyte serum plus complement (T-ATS). A
second test, likewise, confirmed this with similar results, using the E-rosette method with SRBC
(T-E). B-cells in healthy thymus were low (0-30/0)' when measured by the EAC-rosette method
employing SRBC and anti-SRBC antibody with mouse complement.
However, in tests on myasthenic thymus cells the proportion of T-cells was low (43-88%),
On the other hand, B-cells were found to be significantly higher (10-35°A» than for healthy thymus
cells. Furthermore, the use of these two testing methods, Le. T-E and T-ATS, provided a noticea-
ble difference between their results in the total T-cell counts for each group.
A further item of interest was detected by the dissociation between the proportion of T-ATS
and T-E for myasthenic cells. In most cases, healthy thymus cells were sensitive to even the
lowest concentrations of ATS (1 :2,408). On the other hand, some myasthenic thymus cells seem
to have a low amount of thymic antigen, even at high concentrations, since they were not killed
by higher dilutions of ATS. This tendency was similar for both cell samples collected from
thymomatous and non-thymomatous areas of myasthenic patients.
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